Understanding how ERK contributes to KRAS-driven pancreatic cancer
Mechanistic Basis for ERK in driving KRAS-dependent pancreatic cancer
['FUNDING_OTHER'] · HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES · NIH-11212943
This study is looking at how a specific pathway in cells affects the growth of pancreatic cancer with KRAS gene mutations, and it aims to find new ways to make treatments work better for patients dealing with this type of cancer.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES (nih funded) |
| Locations | 1 site (EAST LANSING, UNITED STATES) |
| Trial ID | NIH-11212943 on ClinicalTrials.gov |
What this research studies
This research investigates the role of the ERK signaling pathway in the growth of pancreatic cancer cells that have mutations in the KRAS gene. By analyzing how ERK influences cancer cell behavior, the study aims to identify new strategies to overcome resistance to existing KRAS-targeted therapies. The approach includes genetic analyses and testing of potential inhibitors to improve treatment outcomes for patients with KRAS-mutant pancreatic cancer. Patients may be involved in trials that explore these new therapeutic options.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who have mutations in the KRAS gene.
Not a fit: Patients with pancreatic cancer that does not involve KRAS mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with KRAS-mutant pancreatic cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown that targeting the KRAS pathway can lead to significant tumor shrinkage, although challenges remain in overcoming resistance, indicating both potential and the need for further exploration.
Where this research is happening
EAST LANSING, UNITED STATES
- HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES — EAST LANSING, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KLOMP, JENNIFER E — HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES
- Study coordinator: KLOMP, JENNIFER E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy, Cancer Cause, cancer cell, Cancer Etiology, Cancer Genes